Replimune (REPL) Share-based Compensation (2017 - 2026)
Replimune (REPL) posted Share-based Compensation of $8.1 million for Q1 2026, up 15.3% sequentially from $7.0 million in Q4 2025, and down 1.87% YoY from $8.3 million in Q1 2025.
Replimune (REPL) Share-based Compensation (2017 - 2026) Analysis & Trends
Replimune has reported Share-based Compensation for 10 years, with the latest figure at $8.1 million in Q1 2026.
- Quarterly Share-based Compensation fell 1.87% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (down 7.91% YoY) and the FY2026 annual result came in at $32.3 million, down 7.91% from the prior year.
- Share-based Compensation rose to $8.1 million in Q1 2026 per REPL's latest filing, from $7.0 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $9.5 million in Q2 2024 and troughed at $5.8 million in Q1 2022.
- A 5-year average of $8.0 million and a median of $8.2 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 66.27% in 2022, then fell 18.43% in 2025.
- Over 5 years, Share-based Compensation stood at $7.0 million in 2022, then gained by 17.33% to $8.2 million in 2023, then grew by 4.84% to $8.6 million in 2024, then dropped by 18.43% to $7.0 million in 2025, then climbed by 15.3% to $8.1 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $8.1 million, $7.0 million, and $8.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 8.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.13 Mn |
| Mar 31, 2026 | 8.13 Mn |
| Dec 31, 2025 | 7.05 Mn |
| Dec 31, 2025 | 7.05 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Sep 30, 2025 | 8.34 Mn |
| Jun 30, 2025 | 8.76 Mn |
| Jun 30, 2025 | 8.76 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Dec 31, 2024 | 8.64 Mn |
| Dec 31, 2024 | 8.64 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Sep 30, 2024 | 8.65 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Jun 30, 2024 | 9.48 Mn |
| Mar 31, 2024 | 7.92 Mn |
| Mar 31, 2024 | 7.92 Mn |
| Dec 31, 2023 | 8.24 Mn |
| Dec 31, 2023 | 8.24 Mn |